BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Vancouver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20180311T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20181104T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20190310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20191103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20191202T080000
DTEND;TZID=America/Vancouver:20191202T170000
DTSTAMP:20260715T015510
CREATED:20191118T152137Z
LAST-MODIFIED:20191118T152137Z
UID:7238-1575273600-1575306000@scienceinboston.com
SUMMARY:Cambridge Biomedical December 2nd - Lunch Event\, Enrollment and Retention in IO studies: Patient and Site Centricity
DESCRIPTION:Overview\n\nEnrollment and Retention in IO studies: Patient and Site Centricity \nAbstract \nEnrollment and patient retention remain the most significant barriers to executing successful randomized clinical trials for sponsor companies today\, impacting timeline\, quality\, and budget.  More than 80% of clinical studies fail to complete enrollment on time\, and approximately half of the sites selected for clinical trials enroll between zero and one patient. \nOvercoming the recruitment challenge requires a sponsor’s delicate coordination of multiple stakeholders\, all of whom have different goals and motivations:  CROs\, vendors\, regulators\, and the two most important partners\, investigators and the patients they are treating. \n  \nRapid developments in the immuno-oncology (IO) field in recent years offer both a challenge and an opportunity for drug developers to design and execute trials with patients and sites in mind (“patient and site centricity”).  The FDA has also evolved in its own patient engagement approach with programs like the Patient-Focused Drug Development (PFDD) initiative. \nKelly Brady\, Vice President\, Clinical Operations Seres Therapeutics \nKelly holds a BS degree in Neuroscience from Lafayette College\, and an MS in Biotechnology from Johns Hopkins where she began her career as a research associate in the Orthopaedic Oncology department.   Kelly  has held positions  of increasing responsibility in Clinical Operations and Clinical Program management over the past 12 years. \n  \nAs a clinical associate at Osiris Therapeutics\, Kelly managed global  pediatric and hematology projects (GVHD\, COPD)\, and was a member of the operational and submission team who worked on Prochymal\, an allogeneic stem cell therapy  which received approval for treatment of GVHD in children in Canada in 2012.  Following Osiris\,  Kelly moved to Millenium/Takeda where she was global phase 3 clinical leader for the Adcetris trials in Hodgkins Lymphoma\,  in conjunction with Seattle Genetics\, run in 29 countries.  Kelly then held positions in Operations and Program management at Acetylon\, and was a member of the team involved in the acquisition of the company by Celgene.  Prior to joining Seres\,  Kelly was  Senior Director\, Global Clinical Program Lead at Akebia\, overseeing the pivotal program including 4 Phase 3  cardiovascular outcomes studies in 27 countries\, and initiated a Clinical Trial Educator program in North America. \n  \nKelly continues to be active with the Leukemia and Lymphoma Society\, and lives in Cambridge with her husband.
URL:https://scienceinboston.com/event/cambridge-biomedical-december-2nd-lunch-event-enrollment-and-retention-in-io-studies-patient-and-site-centricity/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Vancouver:20191202T080000
DTEND;TZID=America/Vancouver:20191202T170000
DTSTAMP:20260715T015510
CREATED:20191118T152137Z
LAST-MODIFIED:20191118T152137Z
UID:27391-1575273600-1575306000@scienceinboston.com
SUMMARY:Cambridge Biomedical December 2nd - Lunch Event\, Enrollment and Retention in IO studies: Patient and Site Centricity
DESCRIPTION:Overview\n\nEnrollment and Retention in IO studies: Patient and Site Centricity \nAbstract \nEnrollment and patient retention remain the most significant barriers to executing successful randomized clinical trials for sponsor companies today\, impacting timeline\, quality\, and budget.  More than 80% of clinical studies fail to complete enrollment on time\, and approximately half of the sites selected for clinical trials enroll between zero and one patient. \nOvercoming the recruitment challenge requires a sponsor’s delicate coordination of multiple stakeholders\, all of whom have different goals and motivations:  CROs\, vendors\, regulators\, and the two most important partners\, investigators and the patients they are treating. \n  \nRapid developments in the immuno-oncology (IO) field in recent years offer both a challenge and an opportunity for drug developers to design and execute trials with patients and sites in mind (“patient and site centricity”).  The FDA has also evolved in its own patient engagement approach with programs like the Patient-Focused Drug Development (PFDD) initiative. \nKelly Brady\, Vice President\, Clinical Operations Seres Therapeutics \nKelly holds a BS degree in Neuroscience from Lafayette College\, and an MS in Biotechnology from Johns Hopkins where she began her career as a research associate in the Orthopaedic Oncology department.   Kelly  has held positions  of increasing responsibility in Clinical Operations and Clinical Program management over the past 12 years. \n  \nAs a clinical associate at Osiris Therapeutics\, Kelly managed global  pediatric and hematology projects (GVHD\, COPD)\, and was a member of the operational and submission team who worked on Prochymal\, an allogeneic stem cell therapy  which received approval for treatment of GVHD in children in Canada in 2012.  Following Osiris\,  Kelly moved to Millenium/Takeda where she was global phase 3 clinical leader for the Adcetris trials in Hodgkins Lymphoma\,  in conjunction with Seattle Genetics\, run in 29 countries.  Kelly then held positions in Operations and Program management at Acetylon\, and was a member of the team involved in the acquisition of the company by Celgene.  Prior to joining Seres\,  Kelly was  Senior Director\, Global Clinical Program Lead at Akebia\, overseeing the pivotal program including 4 Phase 3  cardiovascular outcomes studies in 27 countries\, and initiated a Clinical Trial Educator program in North America. \n  \nKelly continues to be active with the Leukemia and Lymphoma Society\, and lives in Cambridge with her husband.
URL:https://scienceinboston.com/event/cambridge-biomedical-december-2nd-lunch-event-enrollment-and-retention-in-io-studies-patient-and-site-centricity-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191202T180000
DTEND;TZID=America/New_York:20191202T210000
DTSTAMP:20260715T015510
CREATED:20191118T152259Z
LAST-MODIFIED:20191118T152259Z
UID:7241-1575309600-1575320400@scienceinboston.com
SUMMARY:Private Screening: In Their Shoes\, Unheard Stories of Reentry and Recovery
DESCRIPTION:Overview\n\nMassBio will be holding a private screening of In Their Shoes\, Unheard Stories of Reentry and Recovery\, a moving documentary which is set in Boston and explores the connection between mental health\, addiction\, and incarceration. The film will be followed by a panel featuring Dr Bertha Madras of Harvard Medical School and Former US Representative Patrick Kennedy\, both members of President Trump’s Commission on the Opioid Crisis. \nThe documentary recounts the journey of four men from addiction to prison and the complexity of their lives on the outside and is interspersed with interviews and commentary by Mayor Marty Walsh\, Congressman Joe Kennedy III\, Sheriff Michael Bellotti\, Professor Randall Horton\, and more. \nThe screening will be held at the MassBio office\, 300 Technology Square\, Cambridge on December 2nd. Registration and networking with refreshments and hors d’oeuvres will start at 6:00 pm and the documentary will begin at 6:30 pm. \nPlease join us on December 2nd and participate in this critical conversation. Your RSVP response is requested by November 18th\, via email to John Hallinan. \nMore info on the documentary can be found  at https://www.intheirshoesfilm.com/ and additional information on the sobering metrics of opioid abuse at Facts – In Their Shoes Film.
URL:https://scienceinboston.com/event/private-screening-in-their-shoes-unheard-stories-of-reentry-and-recovery/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191202T180000
DTEND;TZID=America/New_York:20191202T210000
DTSTAMP:20260715T015510
CREATED:20191118T152259Z
LAST-MODIFIED:20191118T152259Z
UID:27392-1575309600-1575320400@scienceinboston.com
SUMMARY:Private Screening: In Their Shoes\, Unheard Stories of Reentry and Recovery
DESCRIPTION:Overview\n\nMassBio will be holding a private screening of In Their Shoes\, Unheard Stories of Reentry and Recovery\, a moving documentary which is set in Boston and explores the connection between mental health\, addiction\, and incarceration. The film will be followed by a panel featuring Dr Bertha Madras of Harvard Medical School and Former US Representative Patrick Kennedy\, both members of President Trump’s Commission on the Opioid Crisis. \nThe documentary recounts the journey of four men from addiction to prison and the complexity of their lives on the outside and is interspersed with interviews and commentary by Mayor Marty Walsh\, Congressman Joe Kennedy III\, Sheriff Michael Bellotti\, Professor Randall Horton\, and more. \nThe screening will be held at the MassBio office\, 300 Technology Square\, Cambridge on December 2nd. Registration and networking with refreshments and hors d’oeuvres will start at 6:00 pm and the documentary will begin at 6:30 pm. \nPlease join us on December 2nd and participate in this critical conversation. Your RSVP response is requested by November 18th\, via email to John Hallinan. \nMore info on the documentary can be found  at https://www.intheirshoesfilm.com/ and additional information on the sobering metrics of opioid abuse at Facts – In Their Shoes Film.
URL:https://scienceinboston.com/event/private-screening-in-their-shoes-unheard-stories-of-reentry-and-recovery-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191203T080000
DTEND;TZID=America/New_York:20191203T170000
DTSTAMP:20260715T015510
CREATED:20191118T151945Z
LAST-MODIFIED:20191118T151945Z
UID:27390-1575360000-1575392400@scienceinboston.com
SUMMARY:Technical Seminar: Mass Cytometry for Highly Multiplexed Analysis
DESCRIPTION:Join for a technical seminar and luncheon: Mass Cytometry is advancing analysis. Register to learn more.\n\n\n\n\n\n\nAbout this Event\n\n\nYou are invited to this lunchtime seminar on CyTOF technology. \nAbstract: Revealing cellular variations in perceived homogenous populations has become crucial to characterizing immune responses\, understanding cancer cells\, tracking stem cell lineage\, and studying the effectiveness of biological therapies. Additionally\, the need for antibody-based high parameter protein analysis is underscored by its capacity to identify rare and previously uncharacterized cell populations. This ability has far reaching implications in both basic research and into translational research. \nSpeakers: \nDaniel Frederick\, PhD\, Mass Cytometry Application Scientist \nEric Swanson\, PhD\, Imaging Mass Cytometry Application Scientist \nIn this seminar: \n(a) we will describe the principles of the Helios™\, CyTOF® mass cytometry system\, the utility of high parameter analysis\, and highlight ground-breaking research made possible with mass cytometry. \n(b) we will describe the principles and workflow of the Hyperion™ Tissue Imaging System\, and highlight ground-breaking research made possible with imaging mass cytometry.
URL:https://scienceinboston.com/event/technical-seminar-mass-cytometry-for-highly-multiplexed-analysis-2/
LOCATION:Koch Institute for Integrative Cancer Research\, 500 Main Street\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191203T080000
DTEND;TZID=America/New_York:20191203T170000
DTSTAMP:20260715T015510
CREATED:20191118T151945Z
LAST-MODIFIED:20191118T151945Z
UID:7235-1575360000-1575392400@scienceinboston.com
SUMMARY:Technical Seminar: Mass Cytometry for Highly Multiplexed Analysis
DESCRIPTION:Join for a technical seminar and luncheon: Mass Cytometry is advancing analysis. Register to learn more.\n\n\n\n\n\n\nAbout this Event\n\n\nYou are invited to this lunchtime seminar on CyTOF technology. \nAbstract: Revealing cellular variations in perceived homogenous populations has become crucial to characterizing immune responses\, understanding cancer cells\, tracking stem cell lineage\, and studying the effectiveness of biological therapies. Additionally\, the need for antibody-based high parameter protein analysis is underscored by its capacity to identify rare and previously uncharacterized cell populations. This ability has far reaching implications in both basic research and into translational research. \nSpeakers: \nDaniel Frederick\, PhD\, Mass Cytometry Application Scientist \nEric Swanson\, PhD\, Imaging Mass Cytometry Application Scientist \nIn this seminar: \n(a) we will describe the principles of the Helios™\, CyTOF® mass cytometry system\, the utility of high parameter analysis\, and highlight ground-breaking research made possible with mass cytometry. \n(b) we will describe the principles and workflow of the Hyperion™ Tissue Imaging System\, and highlight ground-breaking research made possible with imaging mass cytometry.
URL:https://scienceinboston.com/event/technical-seminar-mass-cytometry-for-highly-multiplexed-analysis/
LOCATION:Koch Institute for Integrative Cancer Research\, 500 Main Street\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191203T100000
DTEND;TZID=America/New_York:20191203T140000
DTSTAMP:20260715T015510
CREATED:20191118T152515Z
LAST-MODIFIED:20191118T152515Z
UID:27393-1575367200-1575381600@scienceinboston.com
SUMMARY:Technical Seminar Lunch-and-Learn Day
DESCRIPTION:The technical seminar you don’t want to miss.\n\n\n\n\n\n\nAbout this Event\n\n\nDevelopment to Market: Early Stage Considerations for Late Stage Success \nFeaturing Patti Seymour of BDO\, Hugh Davis of Frontage Laboratories\, Richard Richieri of Avid Bioservices\, and Arugadoss Devakumar of Avid Bioservices. \n\n\n\n\n\n300 Technology Square
URL:https://scienceinboston.com/event/technical-seminar-lunch-and-learn-day-2/
LOCATION:300 Technology Square\, 300 Technology Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191203T100000
DTEND;TZID=America/New_York:20191203T140000
DTSTAMP:20260715T015510
CREATED:20191118T152515Z
LAST-MODIFIED:20191118T152515Z
UID:7243-1575367200-1575381600@scienceinboston.com
SUMMARY:Technical Seminar Lunch-and-Learn Day
DESCRIPTION:The technical seminar you don’t want to miss.\n\n\n\n\n\n\nAbout this Event\n\n\nDevelopment to Market: Early Stage Considerations for Late Stage Success \nFeaturing Patti Seymour of BDO\, Hugh Davis of Frontage Laboratories\, Richard Richieri of Avid Bioservices\, and Arugadoss Devakumar of Avid Bioservices. \n\n\n\n\n\n300 Technology Square
URL:https://scienceinboston.com/event/technical-seminar-lunch-and-learn-day/
LOCATION:300 Technology Square\, 300 Technology Square\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191203T173000
DTEND;TZID=America/New_York:20191203T183000
DTSTAMP:20260715T015510
CREATED:20191118T152801Z
LAST-MODIFIED:20191118T152801Z
UID:27394-1575394200-1575397800@scienceinboston.com
SUMMARY:Catenion Consulting Info Session
DESCRIPTION:Description\n\n\n\nThis interactive info session will feature current consultants from Catenion\, a multinational company specialized in life-science consulting with officies in Boston\, London\, Berlin and Tokyo. Join us to learn about Catenion’s history and vision\, areas of interest\, work and life at Catenion and how their consultants transitioned into this career path. Participants will have the chance to ask questions and network with the company professionals. \nCatenion is a management consulting firm devoted to helping pharmaceutical and medical products companies create more innovative and effective strategies and organisations. The company draws on their deep understanding of industry trends and company dynamics to help their clients develop actionable competitive strategies. They also address the cultural impediments to pharmaceutical innovation by helping clients create the organisational climates that foster creativity and medical breakthroughs. At the same time they also greatly improve how their clients assess the value and risk of their project and product portfolios and how they allocate resources. \nSign up now to learn more about Catenion!
URL:https://scienceinboston.com/event/catenion-consulting-info-session-2/
LOCATION:MGH\,100 Blossom Street  Cox Floor 3\, Conference room 370\, 100 Blossom Street\, Boston\, MA\, 02114\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191203T173000
DTEND;TZID=America/New_York:20191203T183000
DTSTAMP:20260715T015510
CREATED:20191118T152801Z
LAST-MODIFIED:20191118T152801Z
UID:7247-1575394200-1575397800@scienceinboston.com
SUMMARY:Catenion Consulting Info Session
DESCRIPTION:Description\n\n\n\nThis interactive info session will feature current consultants from Catenion\, a multinational company specialized in life-science consulting with officies in Boston\, London\, Berlin and Tokyo. Join us to learn about Catenion’s history and vision\, areas of interest\, work and life at Catenion and how their consultants transitioned into this career path. Participants will have the chance to ask questions and network with the company professionals. \nCatenion is a management consulting firm devoted to helping pharmaceutical and medical products companies create more innovative and effective strategies and organisations. The company draws on their deep understanding of industry trends and company dynamics to help their clients develop actionable competitive strategies. They also address the cultural impediments to pharmaceutical innovation by helping clients create the organisational climates that foster creativity and medical breakthroughs. At the same time they also greatly improve how their clients assess the value and risk of their project and product portfolios and how they allocate resources. \nSign up now to learn more about Catenion!
URL:https://scienceinboston.com/event/catenion-consulting-info-session/
LOCATION:MGH\,100 Blossom Street  Cox Floor 3\, Conference room 370\, 100 Blossom Street\, Boston\, MA\, 02114\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191204T073000
DTEND;TZID=America/New_York:20191204T093000
DTSTAMP:20260715T015510
CREATED:20191122T165520Z
LAST-MODIFIED:20191122T165520Z
UID:7301-1575444600-1575451800@scienceinboston.com
SUMMARY:Breakfast at LabShares: Technology Licensing Officers and Associates
DESCRIPTION:Overview\n\nLabShares is a biotech incubator with rentable benches boasting a comprehensive equipment list\, multiple on-site amenities and is staffed by skilled admins available to take the operational tasks off of startups so they can focus on science. \nWe’d like to invite reps from our local licensing offices to come to our space for a delicious\, free breakfast where we’ll present on our model\, benefits and the perks of our space for a company beginning to outgrow their academic incubator. Did we mention our extensive\, free parking? \nThis event is for licensing representatives only; while we appreciate those in sales’ interest in our space\, our information session will be tailored to professionals working in licensing. We ask representatives from sales backgrounds to sign up for our mailing list to keep up to date on events geared towards product marketing and sales professionals.
URL:https://scienceinboston.com/event/breakfast-at-labshares-technology-licensing-officers-and-associates/
LOCATION:LabShares Newton\, LLC\, 90 Bridge Street\, Newton\, MA\, 02458\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191204T073000
DTEND;TZID=America/New_York:20191204T093000
DTSTAMP:20260715T015510
CREATED:20191122T165520Z
LAST-MODIFIED:20191122T165520Z
UID:27397-1575444600-1575451800@scienceinboston.com
SUMMARY:Breakfast at LabShares: Technology Licensing Officers and Associates
DESCRIPTION:Overview\n\nLabShares is a biotech incubator with rentable benches boasting a comprehensive equipment list\, multiple on-site amenities and is staffed by skilled admins available to take the operational tasks off of startups so they can focus on science. \nWe’d like to invite reps from our local licensing offices to come to our space for a delicious\, free breakfast where we’ll present on our model\, benefits and the perks of our space for a company beginning to outgrow their academic incubator. Did we mention our extensive\, free parking? \nThis event is for licensing representatives only; while we appreciate those in sales’ interest in our space\, our information session will be tailored to professionals working in licensing. We ask representatives from sales backgrounds to sign up for our mailing list to keep up to date on events geared towards product marketing and sales professionals.
URL:https://scienceinboston.com/event/breakfast-at-labshares-technology-licensing-officers-and-associates-2/
LOCATION:LabShares Newton\, LLC\, 90 Bridge Street\, Newton\, MA\, 02458\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191204T080000
DTEND;TZID=America/New_York:20191204T100000
DTSTAMP:20260715T015510
CREATED:20191122T165249Z
LAST-MODIFIED:20191122T165249Z
UID:27396-1575446400-1575453600@scienceinboston.com
SUMMARY:Closing The Real-World Evidence Gap: Pragmatic Clinical Trials & Observational Studies
DESCRIPTION:Clinical trials are performed at specialized sites\, with entry criteria that selects subjects likely to show efficacy but who are not necessarily representative of the broad population of patients. There is increasing concern on the part of regulators that explanatory clinical trials\, which confirm a clinical hypothesis\, tend to overestimate the effectiveness and underestimate the safety of medicinal products and devices. The use of real-world evidence to support regulatory decision making is discussed in the FDA final guidance for medical devices (2017) and draft guidance for drugs and biologics (2019). The guidances outline prospective pragmatic clinical trials (PCTs) and retrospective observational studies as the means to bridge the gap between explanatory trials and adoption evaluation. In this forum\, our panel of experts will discuss the evolution and future of PCTs and observational studies as important tools for integration of real-world evidence in medical product development. \nSponsored by the Biostatistics\, Data Management & Clinical Trials (BSDMCT) Forum Working Group.
URL:https://scienceinboston.com/event/closing-the-real-world-evidence-gap-pragmatic-clinical-trials-observational-studies-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191204T080000
DTEND;TZID=America/New_York:20191204T100000
DTSTAMP:20260715T015510
CREATED:20191122T165249Z
LAST-MODIFIED:20191122T165249Z
UID:7299-1575446400-1575453600@scienceinboston.com
SUMMARY:Closing The Real-World Evidence Gap: Pragmatic Clinical Trials & Observational Studies
DESCRIPTION:Clinical trials are performed at specialized sites\, with entry criteria that selects subjects likely to show efficacy but who are not necessarily representative of the broad population of patients. There is increasing concern on the part of regulators that explanatory clinical trials\, which confirm a clinical hypothesis\, tend to overestimate the effectiveness and underestimate the safety of medicinal products and devices. The use of real-world evidence to support regulatory decision making is discussed in the FDA final guidance for medical devices (2017) and draft guidance for drugs and biologics (2019). The guidances outline prospective pragmatic clinical trials (PCTs) and retrospective observational studies as the means to bridge the gap between explanatory trials and adoption evaluation. In this forum\, our panel of experts will discuss the evolution and future of PCTs and observational studies as important tools for integration of real-world evidence in medical product development. \nSponsored by the Biostatistics\, Data Management & Clinical Trials (BSDMCT) Forum Working Group.
URL:https://scienceinboston.com/event/closing-the-real-world-evidence-gap-pragmatic-clinical-trials-observational-studies/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191204T170000
DTEND;TZID=America/New_York:20191204T190000
DTSTAMP:20260715T015510
CREATED:20191118T223826Z
LAST-MODIFIED:20191118T223826Z
UID:27395-1575478800-1575486000@scienceinboston.com
SUMMARY:Careers after PhD: A Panel Discussion and Networking Event for Life Science PhDs
DESCRIPTION:STEMCELL Technologies and Science in Boston invite you to attend an exclusive career and networking night exploring science careers outside of academia. The evening will feature keynote speaker Dr. Nicole Quinn\, Associate Director of Scientific Communications at STEMCELL Technologies\, who will discuss her career transition from academia to science communications and offer tangible advice for identifying and pursuing various careers outside of academic research. This will be followed by a panel discussion with industry experts\, who will share their experience and expertise in a myriad of career options. Food and refreshments will be provided. \nPlease RSVP before December 1 to reserve your spot! \n\n\nKeynote Speaker\n\n\n\n\n\n\nNicole Quinn\, PhD\nAssociate Director\, Scientific Communications\nSTEMCELL Technologies\n\n\n\n\n\n\n\n\nPanelists\n\n\n\n\n\n\nMichelle Stolzoff\, PhD\nSr. Technical Writer\nTakeda\n\n\n\n\n\n\n\n\n\nRachit Neupane\, PhD\nSenior Associate\nClarion Healthcare\n\n\n\n\n\n\n\n\n\n\nBenjamin Arellano\, PhD\nImmunology and Cell Separation Specialist\nSTEMCELL Technologies\n\n\n\n\n\n\n\n\n\n\nCarla D’Avanzo\, PhD\nStrategic Alliances Program Manager\nMass General Research Institute\n\n\n\n\n\n\n\n\n\nTime:Wednesday\, December 4\, 5:00 p.m. – 7:00 p.m. \nLocationSTEMCELL Technologies Inc. Cambridge Office\n222 Third Street\, Suite 2323\, Cambridge\, MA
URL:https://scienceinboston.com/event/careers-after-phd-a-panel-discussion-and-networking-event-for-life-science-phds-2/
LOCATION:STEMCELL Tech\, Suite 2323-222 Third Street\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191204T170000
DTEND;TZID=America/New_York:20191204T190000
DTSTAMP:20260715T015510
CREATED:20191118T223826Z
LAST-MODIFIED:20191118T223826Z
UID:7258-1575478800-1575486000@scienceinboston.com
SUMMARY:Careers after PhD: A Panel Discussion and Networking Event for Life Science PhDs
DESCRIPTION:STEMCELL Technologies and Science in Boston invite you to attend an exclusive career and networking night exploring science careers outside of academia. The evening will feature keynote speaker Dr. Nicole Quinn\, Associate Director of Scientific Communications at STEMCELL Technologies\, who will discuss her career transition from academia to science communications and offer tangible advice for identifying and pursuing various careers outside of academic research. This will be followed by a panel discussion with industry experts\, who will share their experience and expertise in a myriad of career options. Food and refreshments will be provided. \nPlease RSVP before December 1 to reserve your spot! \n\n\nKeynote Speaker\n\n\n\n\n\n\nNicole Quinn\, PhD\nAssociate Director\, Scientific Communications\nSTEMCELL Technologies\n\n\n\n\n\n\n\n\nPanelists\n\n\n\n\n\n\nMichelle Stolzoff\, PhD\nSr. Technical Writer\nTakeda\n\n\n\n\n\n\n\n\n\nRachit Neupane\, PhD\nSenior Associate\nClarion Healthcare\n\n\n\n\n\n\n\n\n\n\nBenjamin Arellano\, PhD\nImmunology and Cell Separation Specialist\nSTEMCELL Technologies\n\n\n\n\n\n\n\n\n\n\nCarla D’Avanzo\, PhD\nStrategic Alliances Program Manager\nMass General Research Institute\n\n\n\n\n\n\n\n\n\nTime:Wednesday\, December 4\, 5:00 p.m. – 7:00 p.m. \nLocationSTEMCELL Technologies Inc. Cambridge Office\n222 Third Street\, Suite 2323\, Cambridge\, MA
URL:https://scienceinboston.com/event/careers-after-phd-a-panel-discussion-and-networking-event-for-life-science-phds/
LOCATION:STEMCELL Tech\, Suite 2323-222 Third Street\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191206T080000
DTEND;TZID=America/New_York:20191206T170000
DTSTAMP:20260715T015510
CREATED:20191122T165805Z
LAST-MODIFIED:20191122T165805Z
UID:7305-1575619200-1575651600@scienceinboston.com
SUMMARY:Yale Lifesciences Pitchfest
DESCRIPTION:Overview\n\nYale Lifesciences Pitchfest is a full day where the top 32 biotech opportunities developing within Yale take the stage to present their 5-minute pitches to industry. The 32 presenting investigators will be competing for $4500 in prizes to be awarded at the end of the day\, but\, more importantly\, all advance as semifinalists in the annual Blavatnik Fund for Innovation at Yale competition\, which will make nearly $3 million in awards in May 2020. \nYale Lifesciences Pitchfest is presented by the Blavatnik Fund for Innovation at Yale.  The Blavatnik Fund helps to accelerate the development of important early-stage discoveries in the life sciences into medical or commercial applications by awarding pilot grants to support exploratory and proof-of-concept activities\, as well as larger development grants for more established projects.  Over its first three years\, the fund has made 21 awards for Yale projects totaling $5 million. \nFor more info see: \nhttps://blavatnik.ocr.yale.edu
URL:https://scienceinboston.com/event/yale-lifesciences-pitchfest/
LOCATION:Alexion Pharmaceuticals\, 100 College St\, New Haven\, CT\, 06510\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191206T080000
DTEND;TZID=America/New_York:20191206T170000
DTSTAMP:20260715T015510
CREATED:20191122T165805Z
LAST-MODIFIED:20191122T165805Z
UID:27398-1575619200-1575651600@scienceinboston.com
SUMMARY:Yale Lifesciences Pitchfest
DESCRIPTION:Overview\n\nYale Lifesciences Pitchfest is a full day where the top 32 biotech opportunities developing within Yale take the stage to present their 5-minute pitches to industry. The 32 presenting investigators will be competing for $4500 in prizes to be awarded at the end of the day\, but\, more importantly\, all advance as semifinalists in the annual Blavatnik Fund for Innovation at Yale competition\, which will make nearly $3 million in awards in May 2020. \nYale Lifesciences Pitchfest is presented by the Blavatnik Fund for Innovation at Yale.  The Blavatnik Fund helps to accelerate the development of important early-stage discoveries in the life sciences into medical or commercial applications by awarding pilot grants to support exploratory and proof-of-concept activities\, as well as larger development grants for more established projects.  Over its first three years\, the fund has made 21 awards for Yale projects totaling $5 million. \nFor more info see: \nhttps://blavatnik.ocr.yale.edu
URL:https://scienceinboston.com/event/yale-lifesciences-pitchfest-2/
LOCATION:Alexion Pharmaceuticals\, 100 College St\, New Haven\, CT\, 06510\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T080000
DTEND;TZID=America/New_York:20191208T120000
DTSTAMP:20260715T015510
CREATED:20191122T170001Z
LAST-MODIFIED:20191122T170001Z
UID:7309-1575792000-1575806400@scienceinboston.com
SUMMARY:Jingle Bell Run
DESCRIPTION:Overview\n\nThe Jingle Bell Run is a fun\, festive race. Together\, we’ll jingle all the way to a cure – and have a fantastic time every step we take!\nBring your friends & family to run or walk and support 1.2 million Massachusetts residents\, including nearly 6\,000 children living with the pain of arthritis.\nGet your jingle on!
URL:https://scienceinboston.com/event/jingle-bell-run/
LOCATION:Boston Common\, Boston Common Corner of Beacon & Charles St.\, Boston\, MA\, 02458\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T080000
DTEND;TZID=America/New_York:20191208T120000
DTSTAMP:20260715T015510
CREATED:20191122T170001Z
LAST-MODIFIED:20191122T170001Z
UID:27399-1575792000-1575806400@scienceinboston.com
SUMMARY:Jingle Bell Run
DESCRIPTION:Overview\n\nThe Jingle Bell Run is a fun\, festive race. Together\, we’ll jingle all the way to a cure – and have a fantastic time every step we take!\nBring your friends & family to run or walk and support 1.2 million Massachusetts residents\, including nearly 6\,000 children living with the pain of arthritis.\nGet your jingle on!
URL:https://scienceinboston.com/event/jingle-bell-run-2/
LOCATION:Boston Common\, Boston Common Corner of Beacon & Charles St.\, Boston\, MA\, 02458\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T113000
DTEND;TZID=America/New_York:20191208T140000
DTSTAMP:20260715T015510
CREATED:20191125T220140Z
LAST-MODIFIED:20191125T220314Z
UID:7360-1575804600-1575813600@scienceinboston.com
SUMMARY:Frontiers in HIV: Sailing in the Scientific Perspective
DESCRIPTION:When HIV first began infecting humans in the 1970s\, scientists were unaware of its existence. Now\, more than 35 million people across the globe live with HIV/AIDS. The medical community\, politicians and support organizations have made incredible progress in the fight against this formerly unknown and heavily stigmatized virus. Despite the fact that infection rates have fallen or stabilized in many countries across the world\,we still have a long way to go. \nCurrent estimates point to the number of HIV-positive patients in treatment exceeding the number of new infections. Throughout its history\, the number of new infections has always outweighed the number of patients in treatment. In light of this new data\, it looks like scientists may finally take the lead in the battle against the global AIDS epidemic. \nRecent scientific advances have brought us closer to the elusive goal of an AIDS vaccine\, but reaching that goal will require broad collaboration to adapt breakthroughs in the sciences that cultivate an understanding of the interactions between HIV and the immune system. \nWith World AIDS Day \, approaching on December 1st\, ECUSA would like to highlight the current advances in HIV research. For this reason\,we have invited 4 highly recognized researchers who stand for the fight against infection. \nDr. Maria Duenas Decamp is an Assistant Professor at UMASS Medical school. She graduated from Universidad Complutense de Madrid and obtained her Ph.D. in Universidad Autónoma de Madrid. Before moving to the USA\, she was a research fellow in the Centro de Investigación Básica de España\, Merck Sharp & Dohme in Spain. She has a broad background in Human immunodeficiency virus type 1 (HIV-1) with specific expertise in areas including HIV-1 tropism\, neutralization\, evolution\, fitness\, and resistance to antiretroviral drugs. She has studied HIV-1 envelopes derived from brain and lymph node tissues to map determinants of macrophage-tropism and sensitivity to neutralizing antibodies (NAbs). She has found new amino acids in specific positions implicated in gp120 structural changes that affect the accessibility of some important regions in the trimer to NAbs. These determinants will be used to develop future immunogens that elicit broadly potent NAbs. Dr. Duenas Decamp has been awarded an R21 and an R01 for this project. She has also been interested in the role of hematopoietic progenitor cells in HIV pathogenesis and in contributing to HIV viral reservoirs in vivo. She was awarded a CFAR Developmental Pilot grant\, and the project was also funded by NIH. \nDr. Fatema Z. Chowdhury (Navin) is a Senior Research Scientist at the Ragon Institute of MGH\, MIT and Harvard in Cambridge. She comes from a diverse scientific training background starting with her undergraduate published studies in bacterial physiology using competitive colonization of mouse intestine by E. coli as a model. She subsequently earned her PhD in Immunology at UT Southwestern Medical Center\, where she published her studies of how innate inflammatory cytokines regulate CD8+ T cell function\, both in mice and humans. She is interested in further studying host-pathogen interaction and joined the Ragon Institute as a postdoctoral fellow in 2014 to study HIV-1 pathogenesis and immunity. She has always been very active in outreach as well\, such as participating in fundraising events raising awareness about HIV and AIDS in the community. \nDr. Andrew J. Anderson did his Ph.D. at the University of California\, Riverside\, in Kenneth Dorshkind’s lab\, where he studied how bone marrow microenvironments influence B lymphocyte development. He then moved to Columbia University\, to work in Kathryn Calame’s lab and focused on T cell-specific gene expression. During this time\, he began exploring how cell-specific transcription factors influence HIV replication\, which has been the primary focus of his research as an independent investigator. His first position as an independent investigator was at Penn State University in the Department of Veterinary and Biomedical Sciences\, where activities included being a co-director of the Immunobiology Graduate Program\, Director of the Immunology and Infectious Diseases Undergraduate Program and Director of the Center for Immunology and Infectious Diseases. He moved to Boston University School of Medicine\, Department of Medicine and Section of Infectious Diseases in 2007\, and his institutional activities include Assistant Dean of Graduate Medical Sciences\, Co-director of the Providence/Boston Center for AIDS Research\, Director of the BU PREP post-Bac program and developing international training programs. \nDr. Daniel Claiborne is a senior postdoctoral fellow in the laboratory of Dr. Todd Allen at the Ragon Institute of MGH\, MIT\, and Harvard. In 2014 he received his Ph.D. in Immunology and Molecular Pathogenesis from Emory University. During his graduate work\, he helped to define the integral role of transmitted viral characteristics\, such as replicative capacity\, in determining many aspects of HIV-associated pathogenesis and the severity of disease progression. His current work focuses on understanding the potential for novel gene therapy approaches\, including CAR T cell therapy\, to control HIV\, as well as identifying the host and viral factors influencing the selection of transmitted/founder viruses during the HIV-1 transmission bottleneck and the trajectory of disease progression thereafter. \nLogistics for the event: \n11.30-11.40: Event aperture and welcoming \n11.40-12.10: Cells at the service of HIV: Cytotoxic responses to infection\, by Dr. Fatema Z. Chowdhury \n12.10-12.40: HIV models: the use of humanized mice\, by Dr. Daniel Clairborne \n12.40-13.00: Break with light appetizers and coffee \n13.00-13.30: New therapeutic target: Research on effective vaccines\, by Dr. Maria J. Duenas-Decamp \n13.30-14.00: Today HIV latency: Barrier to an effective cure\, by Dr. Andrew J. Henderson \n14.00-14.05: Event closure \nFree event. Limited space. Registration required.
URL:https://scienceinboston.com/event/frontiers-in-hiv-sailing-in-the-scientific-perspective/
LOCATION:MIT Building E51\, MIT Building E51\, 70 Memorial Drive Cambridge\, MA 02142\, Boston\, MA\, 02141\, United States
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2019/11/Capture.png
ORGANIZER;CN="ECUSA":MAILTO:boston@ecusa.es
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191208T113000
DTEND;TZID=America/New_York:20191208T140000
DTSTAMP:20260715T015510
CREATED:20191125T220140Z
LAST-MODIFIED:20191125T220140Z
UID:27411-1575804600-1575813600@scienceinboston.com
SUMMARY:Frontiers in HIV: Sailing in the Scientific Perspective
DESCRIPTION:When HIV first began infecting humans in the 1970s\, scientists were unaware of its existence. Now\, more than 35 million people across the globe live with HIV/AIDS. The medical community\, politicians and support organizations have made incredible progress in the fight against this formerly unknown and heavily stigmatized virus. Despite the fact that infection rates have fallen or stabilized in many countries across the world\,we still have a long way to go. \nCurrent estimates point to the number of HIV-positive patients in treatment exceeding the number of new infections. Throughout its history\, the number of new infections has always outweighed the number of patients in treatment. In light of this new data\, it looks like scientists may finally take the lead in the battle against the global AIDS epidemic. \nRecent scientific advances have brought us closer to the elusive goal of an AIDS vaccine\, but reaching that goal will require broad collaboration to adapt breakthroughs in the sciences that cultivate an understanding of the interactions between HIV and the immune system. \nWith World AIDS Day \, approaching on December 1st\, ECUSA would like to highlight the current advances in HIV research. For this reason\,we have invited 4 highly recognized researchers who stand for the fight against infection. \nDr. Maria Duenas Decamp is an Assistant Professor at UMASS Medical school. She graduated from Universidad Complutense de Madrid and obtained her Ph.D. in Universidad Autónoma de Madrid. Before moving to the USA\, she was a research fellow in the Centro de Investigación Básica de España\, Merck Sharp & Dohme in Spain. She has a broad background in Human immunodeficiency virus type 1 (HIV-1) with specific expertise in areas including HIV-1 tropism\, neutralization\, evolution\, fitness\, and resistance to antiretroviral drugs. She has studied HIV-1 envelopes derived from brain and lymph node tissues to map determinants of macrophage-tropism and sensitivity to neutralizing antibodies (NAbs). She has found new amino acids in specific positions implicated in gp120 structural changes that affect the accessibility of some important regions in the trimer to NAbs. These determinants will be used to develop future immunogens that elicit broadly potent NAbs. Dr. Duenas Decamp has been awarded an R21 and an R01 for this project. She has also been interested in the role of hematopoietic progenitor cells in HIV pathogenesis and in contributing to HIV viral reservoirs in vivo. She was awarded a CFAR Developmental Pilot grant\, and the project was also funded by NIH. \nDr. Fatema Z. Chowdhury (Navin) is a Senior Research Scientist at the Ragon Institute of MGH\, MIT and Harvard in Cambridge. She comes from a diverse scientific training background starting with her undergraduate published studies in bacterial physiology using competitive colonization of mouse intestine by E. coli as a model. She subsequently earned her PhD in Immunology at UT Southwestern Medical Center\, where she published her studies of how innate inflammatory cytokines regulate CD8+ T cell function\, both in mice and humans. She is interested in further studying host-pathogen interaction and joined the Ragon Institute as a postdoctoral fellow in 2014 to study HIV-1 pathogenesis and immunity. She has always been very active in outreach as well\, such as participating in fundraising events raising awareness about HIV and AIDS in the community. \nDr. Andrew J. Anderson did his Ph.D. at the University of California\, Riverside\, in Kenneth Dorshkind’s lab\, where he studied how bone marrow microenvironments influence B lymphocyte development. He then moved to Columbia University\, to work in Kathryn Calame’s lab and focused on T cell-specific gene expression. During this time\, he began exploring how cell-specific transcription factors influence HIV replication\, which has been the primary focus of his research as an independent investigator. His first position as an independent investigator was at Penn State University in the Department of Veterinary and Biomedical Sciences\, where activities included being a co-director of the Immunobiology Graduate Program\, Director of the Immunology and Infectious Diseases Undergraduate Program and Director of the Center for Immunology and Infectious Diseases. He moved to Boston University School of Medicine\, Department of Medicine and Section of Infectious Diseases in 2007\, and his institutional activities include Assistant Dean of Graduate Medical Sciences\, Co-director of the Providence/Boston Center for AIDS Research\, Director of the BU PREP post-Bac program and developing international training programs. \nDr. Daniel Claiborne is a senior postdoctoral fellow in the laboratory of Dr. Todd Allen at the Ragon Institute of MGH\, MIT\, and Harvard. In 2014 he received his Ph.D. in Immunology and Molecular Pathogenesis from Emory University. During his graduate work\, he helped to define the integral role of transmitted viral characteristics\, such as replicative capacity\, in determining many aspects of HIV-associated pathogenesis and the severity of disease progression. His current work focuses on understanding the potential for novel gene therapy approaches\, including CAR T cell therapy\, to control HIV\, as well as identifying the host and viral factors influencing the selection of transmitted/founder viruses during the HIV-1 transmission bottleneck and the trajectory of disease progression thereafter. \nLogistics for the event: \n11.30-11.40: Event aperture and welcoming \n11.40-12.10: Cells at the service of HIV: Cytotoxic responses to infection\, by Dr. Fatema Z. Chowdhury \n12.10-12.40: HIV models: the use of humanized mice\, by Dr. Daniel Clairborne \n12.40-13.00: Break with light appetizers and coffee \n13.00-13.30: New therapeutic target: Research on effective vaccines\, by Dr. Maria J. Duenas-Decamp \n13.30-14.00: Today HIV latency: Barrier to an effective cure\, by Dr. Andrew J. Henderson \n14.00-14.05: Event closure \nFree event. Limited space. Registration required.
URL:https://scienceinboston.com/event/frontiers-in-hiv-sailing-in-the-scientific-perspective-2/
LOCATION:MIT Building E51\, MIT Building E51\, 70 Memorial Drive Cambridge\, MA 02142\, Boston\, MA\, 02141\, United States
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2019/11/Capture.png
ORGANIZER;CN="ECUSA":MAILTO:boston@ecusa.es
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T083000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T015510
CREATED:20191125T155225Z
LAST-MODIFIED:20191125T155225Z
UID:27400-1575966600-1575982800@scienceinboston.com
SUMMARY:The Diversity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry
DESCRIPTION:Overview\n\nMassBio\, in partnership with SVB Leerink\, WEST and  Silicon Valley Bank is hosting an invite-only event to bring together the best and brightest minds in the life sciences and healthcare industry for a thoughtful discussion on how we can make our workforce\, workplace\, and marketplace more inclusive. You will hear from thought-provoking industry leaders\, enjoy interactive sessions with actionable insights to positively impact our community\, and benefit from meaningful networking opportunities to encourage good diversity of thought. \nPlease email Edie Stringfellow if you are interested in attending. \n\nOur Workforce – Who we hire and how we hire matters. How do we build I&D into our workforce by focusing on our hiring practices and hiring decisions\, the processes we undertake to evaluate potential employees and where we go to recruit them etc.?\nOur Workplace – Once we’ve hired great people\, how do we keep and develop them?\nOur Marketplace – How do we become more deliberate to ensure the diverse perspectives and needs of our customers and communities are taken into consideration?\n\nWe hope to help change views from having D&I being seen as a challenge\, to being embraced as an invaluable opportunity to make our employees\, our business\, and our industry stronger. Click here for more details\, full agenda and speaker information. \n  \nDate: \nTuesday\, December 10\, 2019\n8:30 a.m. – 1:00 p.m. \nAdd to My Calendar \n  \nLocation: \nConvene \n201 Washington Street\, 2nd Floor \nBoston\, MA 02108
URL:https://scienceinboston.com/event/the-diversity-inclusion-forum-perspectives-possibilities-for-the-life-science-industry-2/
LOCATION:Convene\, 201 Washington Street\, 2nd Floor\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T083000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T015510
CREATED:20191125T155225Z
LAST-MODIFIED:20191125T155225Z
UID:7324-1575966600-1575982800@scienceinboston.com
SUMMARY:The Diversity & Inclusion Forum: Perspectives & Possibilities for the Life Science Industry
DESCRIPTION:Overview\n\nMassBio\, in partnership with SVB Leerink\, WEST and  Silicon Valley Bank is hosting an invite-only event to bring together the best and brightest minds in the life sciences and healthcare industry for a thoughtful discussion on how we can make our workforce\, workplace\, and marketplace more inclusive. You will hear from thought-provoking industry leaders\, enjoy interactive sessions with actionable insights to positively impact our community\, and benefit from meaningful networking opportunities to encourage good diversity of thought. \nPlease email Edie Stringfellow if you are interested in attending. \n\nOur Workforce – Who we hire and how we hire matters. How do we build I&D into our workforce by focusing on our hiring practices and hiring decisions\, the processes we undertake to evaluate potential employees and where we go to recruit them etc.?\nOur Workplace – Once we’ve hired great people\, how do we keep and develop them?\nOur Marketplace – How do we become more deliberate to ensure the diverse perspectives and needs of our customers and communities are taken into consideration?\n\nWe hope to help change views from having D&I being seen as a challenge\, to being embraced as an invaluable opportunity to make our employees\, our business\, and our industry stronger. Click here for more details\, full agenda and speaker information. \n  \nDate: \nTuesday\, December 10\, 2019\n8:30 a.m. – 1:00 p.m. \nAdd to My Calendar \n  \nLocation: \nConvene \n201 Washington Street\, 2nd Floor \nBoston\, MA 02108
URL:https://scienceinboston.com/event/the-diversity-inclusion-forum-perspectives-possibilities-for-the-life-science-industry/
LOCATION:Convene\, 201 Washington Street\, 2nd Floor\, Boston\, MA\, 02108\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T100000
DTEND;TZID=America/New_York:20191210T150000
DTSTAMP:20260715T015510
CREATED:20191125T155440Z
LAST-MODIFIED:20191125T155440Z
UID:27401-1575972000-1575990000@scienceinboston.com
SUMMARY:Engaging with Pharma Partners
DESCRIPTION:Overview\n\nJoin us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips\, best practices\, and take advantage of great networking. Lunch will be provided. \n  \nAgenda: \n10:00- Check-in\, Welcome & Introductions \n10:30-11:45 – Panel presentation \n11:45-1:00 – Lunch & Networking \n1:00-3:00 – Optional private 1:1 meeting \n  \nConfirmed: \n  \nImran Nasrullah – Boehringer Ingelheim \n  \nOutcome driven biopharmaceutical leader\, recognized for delivering innovation and being creative\, dynamic\, and cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development\, alliance management\, partnering and licensing activities in diagnostics\, personalized medicine\, therapeutics\, and technology platforms with proven track record from Boehringer Ingelheim\, Massbio\, Genzyme Genetics\, Millennium Pharmaceuticals. \n  \nAlex Lagadinos – Sarepta \n  \n  \nPhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. \n  \nJennifer Ma – Novartis Institutes for BioMedical Research (NIBR) \n  \nJennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions. NIBR is the early R&D unit of Novartis\, responsible for programs from drug discovery stage through early clinical development\, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics. Prior to joining NIBR\, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures\, and started her career setting up a Novartis-academic spin-out. She received a B.A. in Chemistry from Harvard University\, a Ph.D. in organic chemistry from the California Institute of Technology\, and an M.B.A. from Harvard Business School.
URL:https://scienceinboston.com/event/engaging-with-pharma-partners-2/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T100000
DTEND;TZID=America/New_York:20191210T150000
DTSTAMP:20260715T015510
CREATED:20191125T155440Z
LAST-MODIFIED:20191125T155440Z
UID:7328-1575972000-1575990000@scienceinboston.com
SUMMARY:Engaging with Pharma Partners
DESCRIPTION:Overview\n\nJoin us at M2D2 for discussion around how and when startups should engage with pharma partners. Learn tips\, best practices\, and take advantage of great networking. Lunch will be provided. \n  \nAgenda: \n10:00- Check-in\, Welcome & Introductions \n10:30-11:45 – Panel presentation \n11:45-1:00 – Lunch & Networking \n1:00-3:00 – Optional private 1:1 meeting \n  \nConfirmed: \n  \nImran Nasrullah – Boehringer Ingelheim \n  \nOutcome driven biopharmaceutical leader\, recognized for delivering innovation and being creative\, dynamic\, and cross functionally capable. Recipient of Boehringer Ingelheim’s President Award. Extensive experience covering business development\, alliance management\, partnering and licensing activities in diagnostics\, personalized medicine\, therapeutics\, and technology platforms with proven track record from Boehringer Ingelheim\, Massbio\, Genzyme Genetics\, Millennium Pharmaceuticals. \n  \nAlex Lagadinos – Sarepta \n  \n  \nPhD trained molecular biologist with an MBA-level education in bioscience management and over 10 years of experience in research and development. Proven track record of bridging discovery research with business development in order to align strategic initiatives and promote corporate development. Experience with inbound and outbound collaborative transactions and tacit knowledge in rare diseases. \n  \nJennifer Ma – Novartis Institutes for BioMedical Research (NIBR) \n  \nJennifer joined the Novartis Institutes for BioMedical Research (NIBR) in 2015 focusing on licensing and transactions. NIBR is the early R&D unit of Novartis\, responsible for programs from drug discovery stage through early clinical development\, covering all the therapeutic interest areas for Novartis. The licensing team establishes diverse kinds of collaborations with biotech companies and academics. Prior to joining NIBR\, Jennifer held progressively more senior business and licensing roles at AstraZeneca/Medimmune and 5AM Ventures\, and started her career setting up a Novartis-academic spin-out. She received a B.A. in Chemistry from Harvard University\, a Ph.D. in organic chemistry from the California Institute of Technology\, and an M.B.A. from Harvard Business School.
URL:https://scienceinboston.com/event/engaging-with-pharma-partners/
LOCATION:M2D2\, 110 Canal Street\, 4th Floor\, Lowell\, MA\, 01854\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T110000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T015510
CREATED:20191125T155713Z
LAST-MODIFIED:20191125T155713Z
UID:27402-1575975600-1575982800@scienceinboston.com
SUMMARY:Using Machine Learning and Other Methods to Build Predictive QSAR Models
DESCRIPTION:Overview\n\nThis hands-on workshop will focus on using Forge™\, Cresset’s methods for developing 3D and 2D-QSAR models. We will show how to easily apply SVM\, RVM\, Random Forest\, and kNN methods to build multiple models and choose between them; interpret 3D-QSAR models to explain observed SAR; use the models to predict activity for new compound design; use the visual feedback to improve compound design. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Forge will be provided before the event if needed). \nWho should attend: Computational chemists. Some familiarity with alignment in Forge an advantage.
URL:https://scienceinboston.com/event/using-machine-learning-and-other-methods-to-build-predictive-qsar-models-2/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T110000
DTEND;TZID=America/New_York:20191210T130000
DTSTAMP:20260715T015510
CREATED:20191125T155713Z
LAST-MODIFIED:20191125T155733Z
UID:7330-1575975600-1575982800@scienceinboston.com
SUMMARY:Using Machine Learning and Other Methods to Build Predictive QSAR Models
DESCRIPTION:Overview\n\nThis hands-on workshop will focus on using Forge™\, Cresset’s methods for developing 3D and 2D-QSAR models. We will show how to easily apply SVM\, RVM\, Random Forest\, and kNN methods to build multiple models and choose between them; interpret 3D-QSAR models to explain observed SAR; use the models to predict activity for new compound design; use the visual feedback to improve compound design. \nHands-on: If you wish to follow along in this hands-on workshop then please bring a laptop (a download link to Forge will be provided before the event if needed). \nWho should attend: Computational chemists. Some familiarity with alignment in Forge an advantage.
URL:https://scienceinboston.com/event/using-machine-learning-and-other-methods-to-build-predictive-qsar-models/
LOCATION:CIC\, Charles Room\, 14th Floor\, CIC\, 1 Broadway\, Cambridge\, MA\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T160000
DTEND;TZID=America/New_York:20191210T180000
DTSTAMP:20260715T015510
CREATED:20191125T155941Z
LAST-MODIFIED:20191125T155941Z
UID:7334-1575993600-1576000800@scienceinboston.com
SUMMARY:Value Of Health Part III: Potential Disruptors' Impact To Value\, Access & Reimbursement
DESCRIPTION:This event\, Part III in a three part series that will explore the value of health\, will consider disruptions to the ever-evolving value\, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing\, patient access\, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more\, with MassBio’s Bob Coughlin as the moderator. \nWe believe this issue is especially timely. We’re at an inflection point\, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action\, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies\, government or other stakeholders will – and they will likely get it wrong. \nDrinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending\, please email contact us at communications@massbio.org.
URL:https://scienceinboston.com/event/value-of-health-part-iii-potential-disruptors-impact-to-value-access-reimbursement/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191210T160000
DTEND;TZID=America/New_York:20191210T180000
DTSTAMP:20260715T015510
CREATED:20191125T155941Z
LAST-MODIFIED:20191125T155941Z
UID:27403-1575993600-1576000800@scienceinboston.com
SUMMARY:Value Of Health Part III: Potential Disruptors' Impact To Value\, Access & Reimbursement
DESCRIPTION:This event\, Part III in a three part series that will explore the value of health\, will consider disruptions to the ever-evolving value\, access & reimbursement landscape as new players enter the arena and others consolidate. What impact will mergers between payers and PBMs have on drug pricing\, patient access\, and the ability to track and analyze data? How are digital technologies changing the way we track patients and ensure access? What impact will one-time cures have on the system? What new financing methodologies are gaining traction and what else can we do to support their widespread adoption?  What new players are disrupting the value equation? We’ll attempt to answer those questions and more\, with MassBio’s Bob Coughlin as the moderator. \nWe believe this issue is especially timely. We’re at an inflection point\, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action\, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies\, government or other stakeholders will – and they will likely get it wrong. \nDrinks and appetizers will be provided. If you’re not a MassBio member but are interested in attending\, please email contact us at communications@massbio.org.
URL:https://scienceinboston.com/event/value-of-health-part-iii-potential-disruptors-impact-to-value-access-reimbursement-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
END:VCALENDAR